|Bid||105.00 x 0|
|Ask||120.00 x 0|
|Day's range||103.89 - 118.90|
|52-week range||55.10 - 345.00|
|Beta (5Y monthly)||-0.66|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2023 - 24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Sareum Holdings PLC (“Sareum” or the “Company”) Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory AgencySareum has made significant progress advancing SDC-1801 towards clinical development and plans to initiate Phase 1 clinical trials in 2022, with
The big shareholder groups in Sareum Holdings plc ( LON:SAR ) have power over the company. Generally speaking, as a...